SUCCESSFUL MEDICATION THERAPY OF ACUTE RIGHT VENTRICLE INSUFFICIENCY IN RECIPIENT WITH SIGNIFICANT PULMONARY HYPERTENSION AFTER HEART TRANSPLANTATION

Acute right ventricular failure in the early period after orthotopic heart transplantation is a severe complication and can often lead to a fatal outcome. This is especially important in patients with high pulmonary arteries resistance. Drug therapy has shown effectiveness only for the treatment of primary pulmonary hypertension. Patient K., 23 years old with signifi cant pulmonary hypertension (mean pulmonary artery pressure of 60 mm Hg, PVR – 6 Wood units) underwent orthotopic heart transplantation. Acute right ventricular failure occurred at early postoperative period which required multicomponent inotropic support. In order to reduce resistance of the pulmonary circulation the patient received sildenafi l (daily dose 50 mg) in combination with inhaled Ventavis (5 mcg a dose every 3 hours) and receipt of Tracleer (bosentan) (at a dose of 125 mg per day). Complex drug therapy resulted in reduction of right ventricular failure, normalization of biochemical parameters. Invasive pulmonary artery pressure decreased to 30 mm Hg and pulmonary vascular resistance was 1.1 Wood units at the moment of discharge. We also revealed right ventricle end-diastolic volume reduction from 70 ml to 62 ml and ejection fraction of the right ventricle (RV EF) increased from 47,7% to 62% in 2 months. Our clinical observation demonstrates the high effi ciency of acute right heart failure complex therapy including inotropic agents in combination with drugs that reduce the pulmonary vascular resistance.

1. Чернявский АМ, Ломиворотов ВВ, Бобошко ВА, Корнилов ИА, Князькова ЛГ. Сравнительная оценка профилактического использования внутриаортальной баллонной контрпульсации и левосимендана у пациентов с ИБС с низкой фракцией выброса левого желудочка. Патология кровообращения и кардиохирургия. 2011; 2: 49–54. Chernyavskiy AM, Lomivorotov VV, Boboshko VA, Kornilov IA, Knyaz'kova LG. Sravnitel'naya otsenka profi lakticheskogo ispol'zovaniya vnutriaortal'noy ballonnoy kontrpul'satsii i levosimendana u patsientov s IBS s nizkoy fraktsiey vybrosa levogo zheludochka. Patologiya krovoobrashcheniya i kardiokhirurgiya 2011; 2: 49–54.

2. Behling A, Rohde LE, Colombo FC et al. Effects of 5′-phosphodiesterase four-week long inhibition with sildenafi l in patients with chronic heart failure: a double- blind, placebo-controlled clinical trial. J Card Fail. 2008;14 (3): 189–197.

3. Beiras-Fernandez A, Weis FC, Fuchs H et al. Levosimendan treatment after primary organ failure in heart transplantation: a direct way to recovery? Transplantation. 2006; 82 (8): 1101–1103.

4. Braun S, Schrotter H, Schmeisser A, Strasser RH. Evaluation of pulmonary vascular response to inhaled iloprost in heart transplant candidates with pulmonary venous hypertension. Int J Cardiol. 2007; 115 (1): 67–72.

5. De Santo LS, Mastroianni C, Romano G et al. Role of sildenafi l in acute posttransplant right ventricular dysfunction: successful experience in 13 consecutive patients. Transplant. Proc. 2008; 40 (6): 2015–2018.

6. Guidelines for the diagnosis and treatment of pulmonary hypertension. The task force for the diagnosis and treatment of pulmonary hypertension of the ECS and ERS, endorsed by the ISHLT. Eur. Heart J. 2009; 30: 2493–2537.

7. Kalra PR, Moon JC, Coats AJ. Do results of the ENABLE (Endothelin Antagonist Bosentan for Lowering Cardiac Events in Heart Failure) study spell the end for non-selective endothelin antagonism in heart failure? Int. J. Cardiol. 2002; 85 (2–3): 195–197.

8. Kirklin JK, Naftel DC, Kirklin JW et al. Pulmonary vascular resistance and the risk of heart transplantation. J. Heart Transplant. 1988; 7: 331–335.

9. Langer F, Wendler O, Wilhelmf W et al. Treatment of a case of acute right heart failure by inhalation of iloprost, a long-acting prostacyclin analogue. European Journal of Anaesthesiology. 2001; 18: 770–773.

10. Larry M. Baddour, M.D., Yong-Mei Cha, M.D., and Walter R. Wilson, M.D. Infections of Cardiovascular Implantable Electronic Devices. N Engl J Med. 2012; 367: 842–849.

11. Lewis GD, Shah R, Shahzad K et al. Sildenafi l improves exercise capacity and quality of life in patients with systolic heart failure and secondary pulmonary hypertension. Circulation. 2007; 116 (14): 1555–1562.

12. Lima B, Rajagopal K, Petersen RP et al. Marginal cardiac allografts do not have increased primary graft dysfunction in alternate list transplantation. Circulation. 2006; 114 (1): I27–I32.

13. Listijono R, Watson A, Pye R et al. Usefulness of extracorporeal membrane oxygenation for early cardiac allograft dysfunction. Journal of Heart and Lung Transplantation. 2011; 30 (7): 783–789.

14. Luscher TF, Enseleit F, Pacher R et al. Hemodynamic and neurohumoral effects of selective endothelin A (ET(A)) receptor blockade in chronic heart failure: the Heart Failure ET(A) Receptor Blockade Trial (HEAT). Circulation. 2002; 106 (21): 2666–2672.

15. Marasco SF, Vale M, Pellegrino V et al. Extracorporeal membrane oxygenation in primary graft failure after heart transplantation. Annals of Thoracic Surgery. 2010; 90 (5): 1541–1546.

16. Murali S, Kormos RL, Uretsky BF et al. Preoperative pulmonary hemodynamics and early mortality after orthotopiccardiac transplantation: the Pittsburgh experience. American Heart Journal. 1993; 126 (4): 896–904.

17. O’Brien JD, Ferguson JH, Howlett SE. Effects of ischemia and reperfusion on isolated ventricular myocytesfrom young adult and aged Fischer 344 rat hearts. American Journal of Physiology. 2008; 294 (5): H2174–H2183.

18. Olschewski H, Hoeper MM, Behr J et al. Long-term therapy with inhaled iloprost in patients with pulmonary hypertension. Respir. Med. 2010; 104: 731–740.

19. Oto T, Excell L, Griffi ths AP et al. Association between primary graft dysfunction among lung, kidney and heart recipients from the same multiorgan donor. American Journal of Transplantation. 2008; 8 (10): 2132–2139.

20. Russo MJ, Iribarne A, Hong KN et al. Factors associated with primary graft failure after heart transplantation. Transplantation. 2010; 90 (4): 444–450.

21. Sarsam MA, Campbell CS, Yonan NA et al. An alternative technique in orthotopic cardiac transplantation. J. Card. Surg. 1993; 8: 344–349.

22. Scheiermann P, Beiras-Fernandez A, Mutlak H, Weis F. The protective effects of levosimendan on ischemia/ reperfusion injury and apoptosis. Recent Patents on Cardio vascular Drug Discovery. 2011; 6 (1): 20–26.

23. Schroeder RA, Wood GL, Plotkin JS, Kuo PC. Intraoperative use of inhaled PGI2 for acute pulmonary hypertension and right ventricular failure. Anesth. Analg. 2000; 91: 291–295.

24. Stehlik J, Edwards LB, Kucheryavaya AY et al. The registry of the international society for heart and lungtransplantation: twenty-seventh offi cial adult heart transplant report 2010. Journal of Heart and Lung Transplantation. 2010; 29 (10): 1089–1103.

25. Torres Macho J, Delgado Jimenez JF, Sanz Salvo J et al. Effect of different pharmacologic agents to reverse severe pulmonary hypertension among end-stage heart failure patients. Transplant. Proc. 2009; 41 (6): 2477–2479.